Company Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis.
It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure.
The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.
Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
| Country | FR |
| IPO Date | Mar 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 169 |
| CEO | M. Pascal Prigent |
Contact Details
Address: Parc EurasantE Loos, FR | |
| Website | https://www.genfit.com |
Stock Details
| Ticker Symbol | GNFT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001757064 |
| CUSIP Number | 372279109 |
| ISIN Number | US3722791098 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| M. Pascal Prigent | Chief Executive Officer |
| Dr. Meriam Kabbaj Ph.D. | Chief Technology Officer |
| Pascal Caisey | Chief Operating Officer |
| Thomas Baetz | Chief Financial Officer |
| Dr. Dean W. Hum Ph.D. | Chief Scientific Officer |
| Jean-Christophe Marcoux | Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG |
| Jean-Francois Mouney | Co-Founder & Chairman of the Board |
| Laurent Lannoo | Corporate Secretary & Director of Legal Affairs |
| Prof. Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board |
| Stefanie Magner J.D. | Chief Compliance Officer & Executive Vice President of International Legal Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Filing |
| Nov 07, 2024 | 6-K | Filing |
| Sep 23, 2024 | 6-K | Filing |
| Sep 19, 2024 | 6-K | Filing |
| Sep 19, 2024 | 6-K | Filing |
| Jul 26, 2024 | 6-K | Filing |
| Jul 09, 2024 | 6-K | Filing |
| Jun 17, 2024 | 6-K | Filing |
| Jun 11, 2024 | 6-K | Filing |
| May 29, 2024 | 6-K | Filing |